|Articles|October 16, 2020
- BioPharm International-10-15-2020
- Volume 2020 eBook
- Issue 3
GMPs Guide COVID-19 Vaccine Manufacturing
Author(s)Feliza Mirasol
Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.
Advertisement
Major bio/pharmaceutical companies and contract service providers leading the charge to bring COVID-19 vaccines to market are familiar with established good manufacturing practices (GMPs). To support manufacturers in the rush to develop a vaccine, FDA, in June 2020, released industry guidance highlighting the development and licensure of COVID-19 vaccines.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 9–10
Citation
When referring to this article, please cite it as F. Mirasol, “GMPs Guide COVID-19 Vaccine Manufacturing," BioPharm International Regulatory Sourcebook eBook (October 2020).
Articles in this issue
almost 5 years ago
Bio/Pharma Industry Works Overtime to Find COVID-19 Therapiesalmost 5 years ago
Viral Vector API Characterization of Product-Related Impuritiesalmost 5 years ago
Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?almost 5 years ago
Tackling Cybersecurity Challenges in Legacy Systemsalmost 5 years ago
Enhancing Process Validation for Sterile Liquid and Freeze-Dried Formsalmost 5 years ago
Due Diligence Assessment of CMC Activitiesalmost 5 years ago
Strong Quality Culture: A How-To for Busy Managersalmost 5 years ago
Resources, Guidelines, and Guidance Documentsalmost 5 years ago
Regulatory and Standard Setting OrganizationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
